The latest warning letters from the US Food and Drug Administration show the agency still is finding manufacturing processes susceptible to diethylene glycol and ethylene glycol substitution and getting no response from some OTC firms to requests for records.
One of the firms targeted in the eight most recent warnings published since early September to OTC drug manufacturers, Zhao...






